Jean Jacques Bienaime, Director at Keros Therapeutics, Inc. (KROS), bought 1,000 shares at $10.61 ($11K) on 2026-07-15, disclosed to the SEC on 2026-07-17.
Scheduled purchase ($11k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KROS | BUY | 2026-06-17 | $10K | — | Filing → |
| IMNM | BUY | 2026-06-09 | $204K | — | Filing → |
| IMNM | SELL | 2026-06-09 | $204K | — | Filing → |